Artelo Biosciences (ARTL) Stock Price, News & Analysis

Company Overview

Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel small-molecule therapies for pain, inflammation, ocular and cardiometabolic disorders. The company leverages a proprietary drug delivery and targeting platform designed to enhance the safety and efficacy profiles of well-characterized active pharmaceutical ingredients. Artelo’s approach is centered on repurposing and optimizing therapeutic molecules to address significant unmet medical needs, with particular emphasis on improving patient tolerability and clinical outcomes.

The company’s lead program, AB101, is an orally bioavailable ion channel modulator in development for neuropathic pain conditions including post-herpetic neuralgia. In parallel, Artelo is advancing AB188, a topical formulation aimed at treating ocular surface diseases such as dry eye syndrome. Earlier-stage preclinical candidates are being explored for inflammatory and cardiometabolic indications, reflecting the versatility of Artelo’s platform technology in shaping molecular properties to target diverse disease pathways.

Founded as a Delaware corporation, Artelo Biosciences is headquartered in Cleveland, Ohio, and conducts research and development activities in the United States. The executive leadership team brings together expertise in medicinal chemistry, pharmaceutical development and regulatory strategy. Artelo continues to engage with key opinion leaders and strategic partners to support its pipeline through proof-of-concept studies and toward eventual regulatory filings.

Key Stats

• Today's Range: $4.85 to $5.75
• 50-Day Range: $4.35 to $28.50
• 52-Week Range: $4.20 to $28.60
• Volume: 190,886 shs
• Average Volume: 120,008 shs
• Market Capitalization: $3.72 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $24.00
• Consensus Rating: Buy

Artelo Biosciences Stock Analysis - MarketRank™

Artelo Biosciences scored higher than 61% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Buy

Consensus Rating

Artelo Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.

Upside Potential

Artelo Biosciences has a consensus price target of $24.00, representing about 352.0% upside from its current price of $5.31.

Amount of Analyst Coverage

Artelo Biosciences has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Artelo Biosciences are expected to grow in the coming year, from ($2.62) to ($1.61) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Artelo Biosciences is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Artelo Biosciences is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Artelo Biosciences has a P/B Ratio of 1.00. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.57% of the float of Artelo Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Artelo Biosciences has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Artelo Biosciences has recently decreased by 29.75%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Artelo Biosciences does not currently pay a dividend.

Dividend Growth

Artelo Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.57% of the float of Artelo Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Artelo Biosciences has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Artelo Biosciences has recently decreased by 29.75%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.36

News Sentiment

Artelo Biosciences has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.93 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Artelo Biosciences this week, compared to 1 article on an average week.

Search Interest

4 people have searched for ARTL on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.

MarketBeat Follows

3 people have added Artelo Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Artelo Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 5.80% of the stock of Artelo Biosciences is held by insiders.

Percentage Held by Institutions

Only 0.87% of the stock of Artelo Biosciences is held by institutions.

ARTL Stock Analysis - Frequently Asked Questions

How have ARTL shares performed this year?

Artelo Biosciences' stock was trading at $6.36 at the beginning of the year. Since then, ARTL shares have decreased by 16.5% and is now trading at $5.31.

How were Artelo Biosciences' earnings last quarter?

Artelo Biosciences, Inc. (NASDAQ:ARTL) posted its quarterly earnings results on Wednesday, August, 13th. The company reported ($5.61) earnings per share for the quarter, missing the consensus estimate of ($0.13) by $5.48.

When did Artelo Biosciences' stock split?

Shares of Artelo Biosciences reverse split on Friday, June 13th 2025.The 1-6 reverse split was announced on Wednesday, June 11th 2025. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 12th 2025. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

Who are Artelo Biosciences' major shareholders?

Artelo Biosciences' top institutional investors include Geode Capital Management LLC (2.29%).
View institutional ownership trends.

How do I buy shares of Artelo Biosciences?

Shares of ARTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Artelo Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Artelo Biosciences investors own include Meta Platforms (META), NVIDIA (NVDA), Broadcom (AVGO), CrowdStrike (CRWD), Advanced Micro Devices (AMD) and Arista Networks (ANET).

Company Calendar

• Last Earnings: 8/13/2025
• Today: 9/14/2025
• Next Earnings (Estimated): 11/10/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ARTL
• CIK: 1621221
• Web: www.artelobio.com
• Phone: (858) 925-7049
• Fax: N/A
• Employees: 5
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Artelo Biosciences: $24.00
• High Price Target: $30.00
• Low Price Target: $18.00
• Potential Upside/Downside: +352.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($19.05)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$9.83 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -497.68%
• Return on Assets: -213.76%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.39
• Quick Ratio: 0.39

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.31 per share
• Price / Book: 1.00

Miscellaneous

• Outstanding Shares: 704,000
• Free Float: 663,000
• Market Cap: $3.74 million
• Optionable: Not Optionable
• Beta: 1.46